Effect of tranilast on facial neuralgia

A phase II study to examine the efficacy and safety of tranilast for trigeminal neuralgia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061230013

Enrollment

Registered

2023-05-12

Start date

2023-10-25

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigeminal neuralgia Trigeminal neuropathic pain

Interventions

Tranilast is administered orally, taking one capsule (100 mg) three times a day.

oral administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who visit Tokushima University Hospital's Department of Fixed Prosthodontics, Temporomandibular Disorder Clinic, Department of Dental Anesthesiology Patients diagnosed with trigeminal neuralgia according to the International Classification of Orofacial Pain Patients aged 50 to 80

Exclusion criteria

Exclusion criteria: Patients with secondary trigeminal neuralgia who find organic changes in the brain by CT or MRI, patients taking warfarin, patients planning to move, pregnant women (especially within about 3 months) or possibly pregnant, patients deemed inappropriate by the principal investigator

Design outcomes

Primary

Measure	Time frame
visual analogue scale	—

Secondary

Measure	Time frame
Precision tactile function inspection value	—

Contacts

Public ContactYoshizo Matsuka

Tokushima University

matsuka@tokushima-u.ac.jp+81-88-633-7350

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026